Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
X. Sun (Amsterdam, Netherlands), E. Peters (Amsterdam, Netherlands), I. Schalij (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), M. Goumans (Leiden, Netherlands), K. Kurakula (Leiden, Netherlands), H. Bogaard (Amsterdam, Netherlands). HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension. 3556

Member's Comments

No comment yet.

Related content which might interest you: Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017 Year: 2018